CompletedPhase 2NCT00602082
Capecitabine and Streptozocin With or Without Cisplatin in Treating Patients With Unresectable or Metastatic Neuroendocrine Tumors
Studying Gastroenteric neuroendocrine neoplasm
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Principal Investigator
- Pippa Corrie, PhD, FRCPCambridge University Hospitals NHS Foundation Trust
- Intervention
- capecitabine(drug)
- Enrollment
- 84 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2009
Study locations (17)
- Basildon University Hospital, Basildon, England, United Kingdom
- Addenbrooke's Hospital, Cambridge, England, United Kingdom
- Cookridge Hospital, Leeds, England, United Kingdom
- Leicester Royal Infirmary, Leicester, England, United Kingdom
- Aintree University Hospital, Liverpool, England, United Kingdom
- UCL Cancer Institute, London, England, United Kingdom
- St. Thomas' Hospital, London, England, United Kingdom
- Mid Kent Oncology Centre at Maidstone Hospital, Maidstone, England, United Kingdom
- Christie Hospital, Manchester, England, United Kingdom
- Clatterbridge Centre for Oncology, Merseyside, England, United Kingdom
- Northern Centre for Cancer Treatment at Newcastle General Hospital, Newcastle upon Tyne, England, United Kingdom
- Oxford Radcliffe Hospital, Oxford, England, United Kingdom
- Royal Marsden - Surrey, Sutton, England, United Kingdom
- Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, England, United Kingdom
- Edinburgh Cancer Centre at Western General Hospital, Edinburgh, Scotland, United Kingdom
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00602082 on ClinicalTrials.govOther trials for Gastroenteric neuroendocrine neoplasm
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07161882ALG-LungCancerRegistry (SAFRO2202)Société Algérienne de Formation et de Recherche en Oncologie
- ACTIVE NOT RECRUITINGPHASE2NCT03110978Stereotactic Body Radiation Therapy With or Without Nivolumab in Treating Patients With Stage I-IIA or Recurrent Non-small Cell Lung CancerM.D. Anderson Cancer Center